כל המחקרים
גיוסPHASE1, PHASE2התערבותי

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

This research study is looking at a new treatment called BEAM-302 for adults who have Alpha-1 Antitrypsin Deficiency (AATD). AATD is a genetic condition that can lead to serious lung and liver problems because the body doesn't make enough of a protective protein. The study has two main parts. The first part (Phase 1) will give different doses of BEAM-302 to a small number of people to see how safe it is and how the body handles it. The second part (Phase 2) will give what seems to be the best dose to more people to learn more about its safety and how well it helps with AATD-related lung or liver disease. The main goal is to find a safe and effective dose of BEAM-302 that could improve health for people living with AATD.

במבט חטוף

סטטוס
גיוס
שלב
PHASE1, PHASE2
נותן חסות
Beam Therapeutics Inc.
יעד הרשמה
192
התחל
19 Jun 2024
השלמה משוערת
01 May 2030

על מה המחקר הזה?

Alpha-1 Antitrypsin Deficiency, often shortened to AATD, is a condition that runs in families. It means your body doesn't produce enough of a protein called alpha-1 antitrypsin, which normally protects your lungs and liver. Without enough of this protective protein, these organs can get damaged over time, leading to lung diseases like emphysema or various liver problems.

Researchers are always looking for new ways to help people with AATD. This study is testing a new medicine called BEAM-302. They want to see if this medicine can increase the levels of the alpha-1 antitrypsin protein in the body, which could then help reduce or prevent damage to the lungs and liver. If successful, BEAM-302 could potentially offer a new treatment option for people living with AATD.

This study will be carried out in stages. Initially, a small group of people will receive BEAM-302 at different doses so doctors can carefully monitor for any side effects and understand how the body processes the medicine. Once a safe and promising dose is identified, more people will take part to gather more information about how well the medicine works and confirm its safety. The overall aim is to find the best way to use BEAM-302 to help people with AATD.

נקודות עיקריות

  • This study is testing a new medicine (BEAM-302) for AATD-related lung and liver problems.
  • It aims to find a safe and effective dose.
  • Participants must have a specific genetic type of AATD (PiZZ mutation).
  • ניטור רפואי צמוד וביקורים סדירים במרפאה יהיו נדרשים.
  • There are specific health requirements and exclusions related to lung and liver health.
  • ההשתתפות היא בהתנדבות, ואתה יכול לפרוש בכל עת.

מי עשוי להיות זכאי?

This study is looking for adults aged between 18 and 70 (inclusive) who have been diagnosed with Alpha-1 Antitrypsin Deficiency (AATD). To be eligible, your AATD must be caused by a specific genetic change, known as the PiZZ mutation, which will be confirmed by a genetic test. Also, your blood levels of the alpha-1 antitrypsin protein must be below a certain level.

There are also some specific health requirements related to your lungs and liver. For example, your lung function (measured by tests called FEV1 and FVC) needs to be within a certain range, and you should show signs of emphysema or have a specific result from another lung test (DLCO). If you are currently receiving augmentation therapy for AATD, you might need to stop this treatment for at least six weeks before joining the study and continue to stop it throughout the study, unless your doctor says otherwise.

However, some health conditions would prevent you from taking part. For instance, if you have severe liver scarring (cirrhosis) or are on a waiting list for a lung or liver transplant, or have previously had certain surgeries like lung volume reduction. People with very severe chest infections often, or a Body Mass Index (BMI) over 30, would also not be able to join. There are also specific rules about liver health, including certain blood test results that might make you ineligible.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. האם אתה בין גיל 18 ל-70?
  2. Have you been diagnosed with AATD and confirmed to have the PiZZ genetic mutation?
  3. Are your blood AAT levels low?
  4. Do you have certain lung function results?
  5. Do you *not* have severe liver scarring (cirrhosis) or severe, frequent chest infections?
  6. Are you *not* waiting for a lung or liver transplant?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you decide to take part in this study, you would first go through a screening process to check if you are eligible based on the criteria mentioned. If eligible, you would receive the study medicine, BEAM-302. This study has two parts. The first part will test different doses of the medicine in small groups, and the second part will use a specific dose in more people.

Throughout the study, you would have regular visits to the clinic. These visits will involve various tests and checks, including blood tests, lung function tests, and scans, to monitor your health, look for any side effects, and see how the medicine is affecting your AATD. The doctors will also want to understand how your body handles the medicine.

It's important to remember that BEAM-302 is an investigational medicine, meaning it's still being tested and is not yet approved for general use. The study duration will vary depending on the phase you are in and your individual needs, but it will involve multiple visits and ongoing assessments over a period of time.

סיכונים ותועלות פוטנציאליים

Taking part in a clinical trial may offer potential benefits, such as gaining access to a new treatment like BEAM-302 before it's widely available, and receiving close medical monitoring from a team of specialists. This study aims to find an effective way to manage AATD, which could improve your health. However, like all medicines, BEAM-302 may have side effects, some of which might be serious or currently unknown. There's also no guarantee that the treatment will work for you. You will be fully informed of all known risks before you decide to participate, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

מיקומים (12)

  • Clinical Study Center
    מיקוד מאומת
    בירמינגהם, ארצות הברית· גיוס
  • Clinical Study Center
    מיקוד מאומת
    בוסטון, ארצות הברית· גיוס
  • Clinical Study Center
    מיקוד מאומת
    צ'רלסטון, ארצות הברית· גיוס
  • Clinical Study Center
    מיקוד מאומת
    אדלייד, אוסטרליה· גיוס
  • Clinical Study Center
    מיקוד מאומת
    פיצרוי, אוסטרליה· גיוס
  • Clinical Study Center
    מיקוד מאומת
    Dublin, Ireland· גיוס
  • Clinical Study Center
    מיקוד מאומת
    ליידן, הולנד· גיוס
  • Clinical Study Center
    מיקוד מאומת
    Auckland, New Zealand· גיוס
  • Clinical Study Center
    מיקוד מאומת
    המילטון, ניו זילנד· גיוס
  • Clinical Study Center
    מיקוד מאומת
    ברמינגהאם, הממלכה המאוחדת· גיוס
  • Clinical Study Center
    מיקוד מאומת
    לונדון, הממלכה המאוחדת· גיוס
  • Clinical Study Center
    מיקוד מאומת
    סאות'המפטון, הממלכה המאוחדת· גיוס

שאלות נפוצות

What is Alpha-1 Antitrypsin Deficiency (AATD)?

AATD is a genetic condition where your body doesn't produce enough of a protective protein. This can lead to damage in your lungs and liver.

What is BEAM-302?

BEAM-302 is a new medicine being tested in this study to see if it can help increase the protective protein levels in people with AATD.

Why is this study being done?

This study aims to find out if BEAM-302 is safe, how well it works, and what the best dose is to help adults with AATD-related lung or liver disease.

Will I have to stop my current AATD treatment?

If you are on augmentation therapy where it's not standard care, you would likely need to stop it for at least 6 weeks before starting the study and throughout, unless your doctor advises otherwise.

What age do I need to be to join?

You need to be between 18 and 70 years old (inclusive) to be considered for this study.

כיצד לגלות עוד

Medical Information

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "A Study to Evaluate the Safety and Efficacy of BEAM-302 in A…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.